natgillin/translations-raw huggingface dataset:
The method of claim 9, wherein at least two different probes are added to the sample wherein a first probe is labelled with a first fluorescent label and is specific for probing Chlamydia trachomatis nucleic acid and a second probe is labelled with a different fluorescent label to the first probe and is specific for probing Neisseria gonorrhoeae nucleic acid. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se uzorku dodaje najmanje dvije različite sonde, gdje je prva sonda obilježena prvim fluorescentnim biljegom i specifična je za sondiranje na nukleinsku kiselinu iz bakterije Chlamydia trachomatis, a druga sonda je obilježena fluorescentnim biljegom različitim od onog za prvu sondu i specifična je za sondiranje na nukleinsku kiselinu iz bakterije Neisseria gonorrhoeae.
reacting a compound of the formula II A-(CH2)m—X II wherein A is as previously defined, m is 0, 1 or 2 and X is a leaving group, with a compound of the formula III 
(a) reakcija spoja formule II A-(CH>)p=X II gdje A je kao prethodno definiran, m je 0, 1 ili 21 X je izlazeća skupina, sa spojem formule III
patients having a Mini-Mental State Examination score of less than or equal to MMSE 24,25,26,27,28 or 29; and 
Mini-Mental State Examination) manje ili jednako 24, 25, 26, 27, 28 ili 29; i
A microorganism introduced with the vector of claim 15. 
Mikroorganizam uveden sa vektorom iz zahtjeva 12.
Moreover, the present invention also provides a method for manufacturing such a food packaging sheet. 
Osim toga, predloženi izum također osigurava postupak za proizvodnju takovih folija za pakiranje hrane.
inputting the measured signal up and the reference signal to the control system for controlling the switches (Sb1, Sb2) so that the measured signal up is substantially in phase with the reference signal representing the input voltage Vac. 
- < unos izmjerenog signala u, 1 referentnog signala u kontrolni sustav radi kontrole sklopki (Sbl, Sb2) tako da je izmjereni signal u, u osnovi u fazi sa referentnim signalom koji predstavlja ulazni napon Vac.
The wet substance was sieved with the aid of an oscillation apparatus of Diaf GS-140 type using a sieve having hole widths of 1,0 mm. 
Vlažna tvar je prosijana pomoću uređaja za potresivanje tipa Diaf GS-140 pomoću sita s veličinom pora od 1,0 mm.
The system of claim 1 wherein the pump is positioned relatively near the fluid container. 
Sustav prema zahtjevu 1, naznačen time što je pumpa postavljena relativno blizu posude s fluidom.
imazamox, its respective isomers a s well as its respective environmentally compatible salts or esters or amides or other derivatives; and quinmerac; 
A) imazamoks, njegove odgovarajuće izomere, kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom; i
the transplanted material is a marginal organ; 
(i) -presađeni materijal je marginalni organ;
TPAP (1.38g) was added and the reaction was allowed to stir under a N2 blanket. 
TPAP (1.38 g) je bio dodan i bilo je omogućeno da se reakcijska smjesa miješa pod pokrivačem od N,.
The injection of claim 3, wherein the injection is consisted of (by weight): 1∼20 parts of 5a-androstane-3B,5,6B-triol, 40∼500 parts of hydroxypropyl-B-cyclodextrin, 1∼100 parts of an isotonic adjusting agent, 0∼200 parts of a freeze drying filler, and 0∼2000 parts of a solvent. A method for preparing the injection of claim 1, comprising steps of 
Injekcija prema patentnom zahtjevu 3, gdje se injekcija sastoji od (po masi): 1~20 dijelova 5a-androstan-3B,5,6B-triola, 40~500 dijelova hidroksipropil-B-ciklodekstrina, 1~100 dijelova izotoničnog sredstva za prilagodbu, 0~200 dijelova punila za ledeno sušenje, te 0~2000 dijelova otapala.
In some embodiments the second flange 48 is provided along the entire periphery of the flange 46 as shown in FIG. 7 (A–A′) and FIG. 8 . 
U nekim ostvarenjima je predviđena druga prirubnica 48 duž cijelog oboda prirubnice 46, kao što je to prikazano na slici 7 (A-A') i na slici 8.
FIG. 18 is a view showing another example of the symbol mapper. 
(od podožralog, Pabikovani j GhikO is simbol sjanja i
Aspect 2. The method of aspect 1, further comprising providing said host cell with a nucleic acid molecule encoding a common light chain. 
Postupak u skladu s patentnim zahtjevom 1, koji dalje sadrži osiguravanje navedene stanice domaćina s molekulom nukleinske kiseline koja kodira zajednički laki lanac.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is the peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
The method of claim 1 wherein the first set of components comprises 30 wt % to 50 wt % alumina particles of mesh size 8×14 and 2 wt % to 10 wt % alumina particles of mesh size −14M. 
Metoda iz bilo kojeg od patentnih zahtjeva 1-4 pri čemu prvi set komponenata obuhvaća 30 wt% do 50 wt% čestica aluminija veličine 2.38 mm *x 1.41 mm (veličina mreže 8 x 14) 12 wt% do 10 wt% čestica aluminija veličine 1.41 mm (veličina mreže - 14M).
This overall pH drop creates a more favourable environment for Ca- and Mg-uptake, due to the improved solubility of these minerals. 
Tim ukupnim sniženjem pH stvara se povoljnija okolina za pohranu Ca i Mg, zahvaljujući boljoj topljivosti tih minerala.
The compound of claim 1 for use according to claim 6 wherein the liver disease is nonalcoholic steatohepatitis (NASH). 
Spoj u skladu s patentnim zahtjevom 1 namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je bolest jetre nealkoholni steatohepatitis (NASH).
The controlled release pharmaceutical composition according to item 33, wherein the amount in a dosage form is 90, 120, 180, 240 or 360 mg active substance. 
Sastav iz patentnog zahtjeva 1, pri čemu je količina u obliku doziranja 90, 120, 180, 240 ili 360 mg dimetilfumarata.
wherein in formulae I, II and III, the residues R1 and R2 are, independent from each other, a C1 to C6 containing straight or branched alkyl group, 
HR P20080463 T3 u čemu su u formulama I do III ostaci R! i R* neovisni jedan o drugom, a C; do Cg sadrže ravnu ili razgranatu alkilnu skupinu,
Separate dosage forms or a package according to any of claims 7-9, wherein said second agent is for separate administration. 
Zasebni dozirni oblici ili pakiranje prema bilo kojem od zahtjeva 9-11, je to drugo sredstvo za posebnu primjenu.
The process of claim 1, wherein the appropriate solvent is water or 50% methanol/water mixture. 
Postupak iz zahtjeva 26, naznačen time da je odgovarajuće otapalo voda ili 50% smjese metanol/voda.
The process of item 30, wherein about 100% of the high molecular weight polyethylene oxide melts. 
Postupak prema zahtjevu 30, naznačen time da se oko 100% polietilen oksida visoke molekulske mase rastopi.
A formulation according toclause7 orclause8, wherein the or each solubilizer is a polyethoxylated fatty acid or a mixture thereof. 
Formulacija sukladno patentnom zahtjevu 5 ili patentnom zahtjevu 6, naznačena time što svaki solubilizator je polietoksilirana masna kiselina ili njihova smjesa.
The immunconjugate of claim 1, wherein the antibody comprises a full-length heavy chain having the amino acid sequence of SEQ ID NO:88, and a full-length light chain having the amino acid sequence of SEQ ID NO:87. 
Imunokonjugat prema zahtjevu 1, naznačen time, da protutijelo obuhvaća: jaki lanac koji ima identitet sekvence barem 90% od aminokiselinske sekvence od SEQ ID NO:88, i/ili
Synthesis of compound (21) 
(21) Broj predmeta:
"Y" is CH2, O or or its pharmaceutically acceptable salts. 
"Y"je CH2, Oili s===0, ili njegove farmaceutski prihvatljive soli.
The method of claim 1, wherein the pluripotent rat cells are characterized by expression of at least one pluripotency marker selected from the group consisting of Dnmt3L, Eras, Err-beta, Fbxo15, Fgf4, Gdf3, Klf4, Lef1, LIF receptor, Lin28, Nanog, Oct4, Sox15, Sox2, and Utf1. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je pluripotentna stanica štakora karakterizirana ekspresijom najmanje jednog pluripotentnog markera izabranog iz skupine koju čine Dnmt3L, Eras, Err-beta, Fbxo15, Fgf4, Gdf3, KIfA4, Lef1, LIF receptora, Lin28, Nanog, Oct4, Sox15, Sox2 1 Utf1.
contacting the antigen presenting cell of step (iii) with a T cell to evaluate the ability of the peptide to simulate the T cell; and 
(iv) stavljanja u kontakt stanice za predočavanje antigena iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da simulira T-stanicu; 1
The combination of claim 1 wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, cervical cancer, sarcoma, brain tumor, gastric cancer, multiple myeloma, leukemia, and lymphoma. 
Spoj prema zahtjevu 10, gdje rak se odabire iz skupine koju čine rak dojke, rak glave i vrata, rak pluća, rak jajnika, rak gušterače, multipli mijelom, kolorektalni rak, rak prostate, melanom, Kaposijev sarkom, Ewingov sarkom, rak jetre, rak želuca, meduloblastom, tumori mozga i leukemija;
A pharmaceutical composition comprising: a therapeutically effective amount of Form B of the hydrochloride salt according to claim 1; and at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća: terapeutski učinkovitu količinu uglavnom čistog kristalnog oblika 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida prema bilo kojem od zahtjeva 1 do 35; i najmanje jedan farmaceutski prihvatljiv nosač, razrjeđivač, posredno sredstvo ili pomoćno sredstvo.
thereby providing a compound of formula (6b): 
ostavljen da reagira sa spojem s formulom (6b):
The method wherein the adverse reaction is any grade of thrombocytopenia. 
Postupak prema zahtjevu 4, pri čemu je neželjena reakcija bilo koji stupanj trombocitopenije.
The immunoassay of claim 13, wherein the sample to be analyzed is selected from the group consisting of blood, urine, and oral fluid. 
Imunokemijsko određivanje iz bilo kojeg od patentnih zahtjeva 9 ili 10, pri čemu je uzorak koji treba analizirati odabran iz grupe koja se sastoji od krvi, urina i usne tekućine.
The term “partial hydrolysis” means that only 20% to 70% by weight of the cellulose at the inlet to the hydrolysis step is hydrolysed. Said solid residue is advantageously separated from the effluent of the enzymatic hydrolysis step, and when it is used, from the effluent of the ethanolic fermentation step. 
Postupak prema zahtjevu 1, naznačen time što se navedeni kruti ostatak dobiva nakon parcijalne enzimske hidrolize, te se hidrolizira 20 do 70% težinskih celuloze na ulazu u korak hidrolize.
A process according to claim 1 wherein the antisolvent B is maintained at a temperature comprised from 0 to 25°C. 
Postupak prema zahtjevu 1 naznačen time što se protuotapalo B održava uz miješanje i pri temperaturi ispod 50°C.
As an example, compositions might consist essentially of artemether or arteether and a pharmaceutically acceptable excipient consisting essentially of a triglyceride, liquid at 37°C, and medium chain triglycerides (as defined herein). Particularly preferred compositions of the invention consist essentially of: artemether or arteether; and one or more pharmaceutically-acceptable excipients selected the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
Kompozicija prema patentnom zahtjevu 1 naznačena time što se uglavnom sastoji od: artemetra ili arteetra; i jednog ili više farmaceutski prihvatljivih inertnih punitelja izabranih iz grupe koju čine: triglideridi srednje dužine lanca; trigliceridi kratkog lanca; omega-3 trigliceridi porijeklom iz mora; i riblje ulje, bogato omega-3-kiselinama pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
is as in formula I, and 
RS je kao u formuli [; i
A method of treating an individual having a disease characterized by Fibroblast Activation Protein (FAP) expression, comprising administering to the individual an effective amount of an antibody that specifically binds to FAP, wherein said antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 267 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 265. 
Protutijelo, naznačeno time, da se specifično veže na fibroblastni aktivatorski protein (FAP), pri čemu to protutijelo obuhvaća varijabilno područje jakog lanca koje se sastoji od sekvence aminokiseline SEK ID BR: 267 i varijabilno područje slabog lanca koje se sastoji od sekvence aminokiseline SEK ID BR: 265.
A compound of Formula (I) or a pharmaceutically acceptable salt thereof 
Å ili njegov solvat, oksid, ili njegova farmaceutski prihvatljiva sol.
The process of claim 7, wherein the amount of citrate ion source, pyrophosphate ion source, and ferric ion source each contain less than 250 micrograms of the metals aluminum, antimony, arsenic, bismuth, cadmium, copper, lead, mercury, molybdenum, thallium, and tin per gram of the ion source. 
Postupak prema zahtjevu 7, gdje količina izvora iona citrata, izvora iona pirofosfata i izvora feri iona svaka sadrži manje od 250 mikrograma metala aluminija, antimona, arsena, bizmuta, kadmija, bakra, olova, žive, molibdena, talija i kositra po gramu izvora iona.
Process for the preparation of vesicles comprising EGF, a cationic surfactant and cholesterol, or derivatives thereof, characterized by comprising: the preparation of an aqueous solution of EGF and a cationic surfactant, preferably wherein the cationic surfactant is of quaternary ammonium type, the dissolution of cholesterol or derivatives thereof in an organic solvent expanded with a CF, preferably wherein the solvent is selected from the group consisting of monohydric alcohols, polyhydric alcohols, ketones, ethylene diamine, acetonitrile, ethyl acetate and mixtures thereof, preferably wherein the CF is a compound selected from carbon dioxide, ethane, propane, hydrochlorofluorocarbons, and hydrofluorocarbons, 
Postupak za pripremu čestica koje sadrže EGF, kationski surfaktant i kolesterol, ili njihove derivate, naznačen time što obuhvaća: a) pripremu vodenog rastvora EGF i kationskog surfaktanta, pri čemu preporučljivo kationski surfaktant predstavlja tip četvorovalentnog amonijaka, b) rastvor kolesterola ili njegovih derivata u organskom rastvoru ekspandiranom s komprimiranim fluidom (CF), preporučljivo pri čemu se rastvor izabire iz grupe koja obuhvaća monohidridne alkohole, polihidridne alkohole, ketone, etilen diamin, acetonitirl, etil acetat i njihove mješavine, preporučljivo pri čemu je komprimirani fluid (CF) spoj izabran iz ugljičnog dioksida, etana, propana, hidroklorofluorougljika, i hidrofluorougljika, c) sinteza čestica pomoću depresurizacije rastvora koji nastaje iz faze b) na rastvoru koji se dobije kao rezultat iz faze a).
The residue was taken up in dichloromethane, and extracted with NaOH (0,1M). 
Ostatak se stavi u diklorometan, i potom ekstrahira s NaOH (0,1 M).
lyophilizing said isolated mature type I elastase, thereby producing a lyophilized mature type I elastase. 
(c) formuliranje zrelog tipa I protein elastaze, na taj način proizvodeći farmaceutski sastav koji sadrži spomenuti zreli tip I protein elastaze.
Characteristic, distinctive and decorative markings are generally printed on the outer paper layer, while the polyethylene layer makes contact with the food in order to provide its best preservation. 
Karakteristične, razlikovne i ukrasne oznake štampaju se općenito na vanjskom papirnatom sloju, dok polietilenski sloj dolazi u dodir s hranom čime se osigurava njezino najbolje očuvanje.
More specifically (FIG. 3), fast cut-off circuit 4 operates as follows. 
Određenije, (Slika 3) komunikacijski krug brzog isključivanja 4 radi kako slijedi.
A liquid rotavirus immunogenic composition suitable for oral administration to a human infant, comprising a rotavirus antigen, a sugar and a carboxylate wherein said formulation has a pH of between about pH 5.0 and about pH 8.0 and comprises less than 1 mM phosphate, wherein said carboxylate is derived from a di-carboxylic acid with an average pKa> 4. 
HR P20110668 T1 PATENTNI ZAHTJEVI Tekući rotavirusni imunogeni pripravak, pogodan za oralnu primjenu na ljudskom dojenčetu, koji sadrži rotavirusni antigen, šećer i karboksilat, naznačen time što navedena formulacija ima pH između otprilike pH 5,0 i otprilike pH 8.0 i sadrži manje od 1 mM fosfata, gdje se navedeni karboksilat dobiva iz dikarboksilne kiseline s prosječnim pX,
(SEQ ID NO: 3) 5′ CTCCCACTGTGACAGCC 3′ In a further aspect of the invention, a method is provided wherein the qPCR of step (ii) further comprises the use of a ‘total’ nucleic acid probe in step (ii) capable of detecting both vaccine and virulent strains. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što qPCR u koraku (ii) dodatno uključuje upotrebu "ukupne" nukleinskokiselinske sonde u koraku (ii), koja može detektirati i cjepivne i virulentne sojeve; gdje ukupna sonda specifična za oba soja može u sebi sadržavati dulji slijed ili se sastojati samo od sljedećeg slijeda ili njegovog fragmenta:
Generator according to any one of claims 13, 14, comprising an inlet duct (11) for introducing the comburant air communicating with said inlet opening (13) of said adjusting device (1). 
Generator sukladno bilo kojem od zahtjeva 13, 14 naznačen time, da se sastoji od ulaznog kanala (11) za uvođenje zraka za poboljšanje sagorijevanja 1 povezan je s navedenim ulaznim otvorom (13) navedenog uređaja za podešavanje (1).
identifying the specific vehicle in the monitoring station through reading the vehicle identification number (VIN); reading the vehicle license plate indicia; or reading a tag positioned on the vehicle including specific vehicle identification indicia. 
identificiranja specifičnog vozila (16) u postaji za praćenje (110) najmanje jednim od očitavanja identifikacijskog broja vozila (VIN) (60); očitavanja registarske oznake vozila; ili očitavanja biljega koji se nalazi na vozilu koje sadrži specifične oznake za identificiranje vozila.
NH-rhGH represents the rhGH residue attached to the transient linker; 
HN-rhGH predstavlja rhGH-ostatak priključen na prijelazni povezni element;
Use of the calcium carbonate materials according to any one of claims 33 to 38 in paper, paints and plastics. 
Uporaba materijala kalcijevog karbonata u skladu s bilo kojim od patentnih zahtjeva 25 do 30 u papiru, bojama i plastici.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:121 and/or a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:120; 
(2) VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 121i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 120;
"arylsulfonyl" means an aryl-S(O2)- group wherein the bond to the parent moiety is through the sulfonyl. 
"arilsulfonil" znači skupina aril-S(O2)-, gdje veza na osnovni ostatak je preko sulfonila.
The antibody or antigen-binding fragment thereof for use of claim 33, wherein the cancer is selected from the group consisting of adenocarcinoma, lymphoma, blastoma, sarcoma, leukemia, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, myeloma, salivary gland carcinoma, kidney cancer, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, and head and neck cancer. 
Antitijelo ili njegov fragment vezan za antigen za uporabu prema zahtjevu 25, naznačeno time što je rak odabran iz skupine koja se sastoji od adenokarcinoma, limfoma, blastoma, sarkoma, leukemije, raka pločastih stanica, malo-staničnog raka pluća, ne-staničnog raka pluća, raka gastrointestinalnog sustava, Hodgkinsovog limfoma, ne-Hodgkinsovog limfoma, raka gušterače, glioblastoma, glioma, raka grlića maternice, raka jajnika, raka jetre, raka mokraćnog mjehura, raka dojke, raka debelog crijeva, kolorektalnog raka, raka endometrije, mijeloma, raka pljuvačne žlijezde, bubrežnog raka, raka bazalnih stanica, melanoma, raka prostate, raka vulve, raka štitnjače, raka testisa, raka jednjaka i raka glave i vrata.
Suitable human constant regions include, for example wild type or modified IgG1, IgG2, IgG3, or IgG4. A mouse whose genome comprises an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with human Vλ and Jλ gene segments, and wherein the human Vλ and Jλ gene segments are operably linked to a mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable sequence fused with a mouse k constant region. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
A capsule for containing a beverage ingredient, the capsule being provided with a dedicated sealing member at its outer face, the sealing member being made from an inelastic material, which sealing member material is different to the material constituting the capsule. 
Čahura koja sadržava sastojak za napitak, pri čemu je čahura (1) snabdjevena s namjenskim elementom za brtvljenje (8) na svojoj vanjskoj strani, pri čemu je element za brtvljenje (8) načinjen od neelastičnog materijala, koji materijal za izradu elementa za brtvljenje je različit od materijala od kojega je načinjena čahura (1), i koji materijal za brtvljenje se može plastično deformirati.
a nucleotide sequence selected from among SEQ ID NOs: 1 - 54 (wherein uracil may be thymine); 
nukleotidna sekvenca koja je odabrana od SEQ ID NO:1 do SEQ ID NO:54 (pri čemu uracil može biti tiamin);
In another embodiment, Form I is further characterized by a peak at 16.6 degrees ± 0.2 degrees. 
Oblik I iz zahtjeva 8, gdje je Oblik I dalje naznačen s pikom na 16,6 stupnjeva.